Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
about
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.Personalization of cancer treatment using predictive simulationNovel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Positioning of proteasome inhibitors in therapy of solid malignancies.
P2860
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Relapsed and refractory lympho ...... a with a focus on carfilzomib.
@en
type
label
Relapsed and refractory lympho ...... a with a focus on carfilzomib.
@en
prefLabel
Relapsed and refractory lympho ...... a with a focus on carfilzomib.
@en
P2093
P2860
P356
P1476
Relapsed and refractory lympho ...... a with a focus on carfilzomib.
@en
P2093
Ajay Nooka
Charise Gleason
Daniela Casbourne
P2860
P356
10.2147/BTT.S24580
P50
P577
2013-01-30T00:00:00Z